Best Mounjaro Alternatives in 2026: FDA‑Approved Options by Cost, Coverage, and Fit

If you’re hunting for the best Mounjaro alternatives, you’re probably not browsing for fun. Your price jumped. Your insurance said no. The side effects wore you down. Or you’re tired of a weekly shot and want a pill.

Here’s the bottom line, up front. For most people switching for weight loss, the closest option is Zepbound — it has the same active ingredient as Mounjaro (tirzepatide), but it’s a different FDA‑approved product, labeled for weight loss, at $299–$449 a month in cash through LillyDirect versus Mounjaro’s $1,112.16 list price. Want a pill instead of a shot? Look at Foundayo or the Wegovy pill (from $149/month). Switching because of side effects? A slower titration or a different molecule may matter more than price. Switching because of a diabetes diagnosis? Skip to the diabetes section below — Zepbound isn’t approved for blood-sugar control.

The part most “top 10” lists get wrong: they hand you a pile of drug names and let you sort it out. We’re going to do the opposite — match the alternative to your reason. And we’ll settle the question about compounded tirzepatide in 2026 straight, with sources.

Ro’s free GLP-1 Insurance Coverage Checker shows what Zepbound, Wegovy, or Ozempic would actually cost on your plan. Free, no prescription needed.

The best Mounjaro alternatives at a glance (2026)

Mounjaro is tirzepatide, FDA‑approved for type 2 diabetes. The strongest FDA‑approved alternatives are Zepbound (same active ingredient, approved for weight loss), Wegovy and Ozempic (semaglutide), and two pills — the Wegovy pill and Foundayo (orforglipron). Compounded GLP‑1s are not FDA‑approved finished drugs and are now tightly restricted.

The table below covers FDA-approved use, average weight loss in studies, and current cash price. Every price is a manufacturer self-pay price verified on the date above. Weight-loss numbers are averages from each drug’s own trials in adults without diabetes — trial designs differ, so treat them as ballparks, not head-to-head guarantees.

Which Mounjaro alternative is right for you?

The right alternative depends on four things: whether you take Mounjaro for weight loss or diabetes, whether you have insurance, whether you’d rather have a shot or a pill, and your reason for switching (cost, coverage, side effects, or access). Match those four and the answer usually becomes clear.

A drug list can’t read your situation. The free GLP-1 matching quiz can. Answer a few quick questions — your goal, your insurance status, shot vs. pill, and why you’re switching — and it points you to the FDA‑approved option that fits, plus the smartest first step. It won’t give you a dose (that’s your prescriber’s job), and it won’t pretend a pill is a shot.

Why are people leaving Mounjaro?

Most people search for Mounjaro alternatives because of one of five things: the $1,112-a-month list price, an insurance or pharmacy-benefit change, the fact that Mounjaro is labeled for diabetes (not weight loss) so plans won’t cover it for weight, side effects, or wanting a pill instead of a weekly injection. Your reason points straight to your best alternative.

Here are the triggers in patients’ own words — shared to show why people search, not as medical evidence:

• “My insurance stopped covering it.” — the single most common trigger. A pharmacy-benefit manager can drop a drug fast: one major one moved its preferred weight-loss drug from Zepbound to Wegovy in mid-2025, and people who had lost real weight got switch letters.
• “I tried Wegovy before Zepbound and it made me profusely ill.” — fear that the alternative won’t be tolerated.
• “At first the coupon made it $25 a month. The next coupon has me paying $500.” — a real patient describing how a savings-card change blew up the price.
• “I called over a dozen pharmacies and still couldn’t get my dose.” — access and supply friction.

Sorted by trigger, here’s where each one points:

“It costs over $1,000 a month.” Mounjaro’s list price is $1,112.16 per fill, and pharmacy cash prices run roughly $990–$1,120 even with a coupon. The famous “$25” deal only works if you have commercial insurance and a diabetes diagnosis. There’s no generic coming (tirzepatide is patent-protected through roughly 2036). → Points to Zepbound.

“My insurance dropped it, or covers diabetes only.” Mounjaro is FDA‑approved for type 2 diabetes, so most plans won’t pay for it just for weight loss, and benefit managers reshuffle their preferred drugs. → Points to Wegovy and the insurance section below.

“It’s for diabetes — but I want it for weight loss.” Using Mounjaro only to lose weight is off-label, which is exactly why coverage is hard. The fix is a drug that’s actually approved for weight loss. → Points to Zepbound, Wegovy, or Foundayo.

“The side effects were too much.” Nausea, vomiting, and stomach trouble are common, especially as the dose goes up. A different medicine, or a slower ramp-up, can help. → Points to the side-effects section.

“I’m done with needles.” Two FDA‑approved pills now exist for weight loss. → Points to the pill section.

Is compounded tirzepatide still a legal Mounjaro alternative in 2026?

Mostly no. After the FDA declared the tirzepatide shortage resolved, mass compounding ended — for state-licensed (503A) pharmacies on February 18, 2025, and for outsourcing facilities (503B) on March 19, 2025. Semaglutide followed (503A on April 22, 2025; 503B on May 22, 2025). In 2026, the FDA says a compounded GLP-1 may be appropriate only when a patient’s medical need can’t be met by an FDA‑approved drug — not for price or convenience alone.

You’ve probably seen ads for “$150 compounded tirzepatide.” Here’s the honest timeline, in order:

• During 2022–2024: GLP-1 shortages allowed 503A and 503B pharmacies to make copies. That’s why “compounded GLP-1” got cheap and everywhere.
• Late 2024: FDA declares the tirzepatide shortage resolved.
• February 2025: FDA declares the semaglutide shortage resolved.
• February 18, 2025: 503A pharmacies must stop mass-compounding tirzepatide.
• March 19, 2025: 503B outsourcing facilities must stop.
• April 22 / May 22, 2025: Same wind-down for semaglutide (503A / 503B).
• April 30, 2026: FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-substance list entirely — courts had denied compounders’ attempts to pause the earlier deadlines. The proposal was still open for public comment at time of writing.

The FDA has also gone after the marketing. On March 3, 2026, it announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1s. On June 16, 2026, it sent another 25 (Reuters). The violations: claims that imply a compounded version is the same as an FDA‑approved drug, and ads that hide who made the medicine.

Why this matters for safety: compounded drugs are not FDA‑approved. The FDA doesn’t review them for safety, effectiveness, or quality before they’re sold, and they are not the same as generics. As of May 31, 2026, the FDA had received 990 reports of adverse events tied to compounded semaglutide and more than 730 tied to compounded tirzepatide — and it says those are likely undercounted. Many cases involved dosing errors serious enough to require hospitalization.

A few hard “don’ts” straight from the FDA’s own warnings:

• Skip “research-grade” or “not for human consumption” peptides sold online — those aren’t medicine, and can be counterfeit, mislabeled, or contaminated.
• Be wary of semaglutide salt forms (sodium or acetate) — the FDA says these are different ingredients than the approved drug, with no lawful basis for compounding use.
• Retatrutide and cagrilintide cannot legally be used in compounding at all.

When compounded can still be appropriate: narrow cases — like a documented allergy to an ingredient in the brand product — under a real prescription from a clinician who’s evaluating you. Price or convenience alone isn’t a compliant reason to copy an approved drug.

We’re not putting a compounded program on the podium as “the best Mounjaro alternative.” Not because cheaper is bad, but because the legitimate cheaper paths in 2026 are the manufacturer self-pay programs you’ve already seen above — and those are far safer bets.

Full context: compounded GLP-1 vs. name brand.

Is Zepbound the closest alternative to Mounjaro?

Yes — for weight loss, Zepbound is usually the closest FDA‑approved alternative to Mounjaro, because it contains the same active ingredient (tirzepatide). The difference is the label and the price: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for weight management and sleep apnea, and Zepbound’s cash price ($299–$449/month) runs far below Mounjaro’s $1,112 list.

Here’s the thing almost nobody says plainly: if you’ve been taking Mounjaro to lose weight, the “alternative” you’re looking for may be the exact same active ingredient — sold under a different name, for the use it’s actually approved for.

Both Mounjaro and Zepbound are tirzepatide — a once-weekly medicine that activates two gut hormones (GIP and GLP-1) to quiet appetite and slow digestion. Same active ingredient. Same dose strengths (2.5 mg up to 15 mg). They are still two distinct FDA‑approved products with different labels. In the head-to-head SURMOUNT-5 trial, tirzepatide led to 20.2% average weight loss at 72 weeks, compared with 13.7% for semaglutide.

What Zepbound actually costs. Through LillyDirect single-dose vials: $299/month at 2.5 mg, $399/month at 5 mg, and $449/month for 7.5 mg through 15 mg. Two honest catches: the vials mean you draw the dose into a syringe yourself (your provider shows you how), and to keep the $449 price you generally need to refill within 45 days — miss that window and higher doses revert to the regular price ($499 at 7.5 mg, or $699 at 10–15 mg).

Who should not switch to Zepbound. If you take Mounjaro for diabetes, Zepbound isn’t a swap — it’s approved for weight loss and sleep apnea, not blood-sugar control. Skip to the diabetes section. And if tirzepatide’s side effects were the problem, a different molecule may suit you better.

If your goal is “Mounjaro, but for weight loss,” this is the cleanest first step. Prefer the lowest sticker price and happy to handle insurance yourself? You can also buy Zepbound vials direct from LillyDirect. See also: best Zepbound alternatives.

Is Wegovy or Ozempic a good Mounjaro alternative?

Semaglutide — sold as Wegovy for weight loss and Ozempic for diabetes — is the most common Mounjaro alternative after Zepbound. It targets one hormone (GLP-1) instead of two, which some people tolerate better. Average weight loss is a bit lower than tirzepatide at standard doses, but the higher-dose Wegovy HD (7.2 mg) gets close (~21% in trials). Cash price is $349/month for the standard Wegovy shot.

If your insurer prefers a Novo Nordisk drug, or if tirzepatide didn’t sit well with you, semaglutide is the natural move.

Wegovy (for weight loss). Wegovy is FDA‑approved for chronic weight management and to lower the risk of serious heart problems in adults with established heart disease and obesity or overweight. In STEP-1, the 2.4 mg dose produced about 14.9% average weight loss at 68 weeks; the 7.2 mg Wegovy HD dose pushes that to roughly 21%. Self-pay through NovoCare: $349/month for standard doses, $399/month for the 7.2 mg version. New self-pay patients can start the two lowest doses at $199/month for two fills through June 30, 2026, then $349.

Ozempic (for diabetes). Ozempic is the same molecule as Wegovy but approved for type 2 diabetes and heart-risk reduction in people with diabetes. It’s a fine diabetes alternative to Mounjaro, but for weight-loss-only use it’s off-label and usually not covered. NovoCare self-pay: $349/month for lower doses, $499/month for 2 mg, with the same $199 intro offer (two fills of the lowest doses through June 30, 2026).

The honest trade-off: tirzepatide tends to win on average weight loss. But “average” isn’t “you.” Some people lose more on semaglutide, tolerate it better, or have a plan that covers it.

Want a pill instead of a shot? Foundayo and the Wegovy pill

Two FDA‑approved daily pills can replace a weekly injection for weight loss: the Wegovy pill (oral semaglutide, from $149/month) and Foundayo (orforglipron, from $149/month, approved April 1, 2026). Foundayo can be taken any time of day with no food or water rules; the Wegovy pill must be taken on an empty stomach. Pills are easier to live with but average a bit less weight loss than tirzepatide shots.

Foundayo (orforglipron) — any time, no food rules

Eli Lilly’s once-daily pill, FDA‑approved on April 1, 2026 for adults with obesity, or overweight plus a weight-related condition. Its big perk: you can take it any time, with or without food or water — no morning ritual. In its ATTAIN-1 trial, people at the top approved dose who stayed on treatment lost about 12.4% of their body weight (27 lb); across everyone who started it, the average was 11.1% (25 lb). Self-pay starts at $149/month; people with commercial insurance may pay as little as $25/month with the savings card. The catch is simply that it’s new, so it has the shortest real-world track record.

More detail: Foundayo cost without insurance · best Foundayo providers

Wegovy pill (oral semaglutide) — proven molecule, fussier routine

A daily tablet version of Wegovy. It works, but it’s fussy: take it on an empty stomach with a small sip of water, then wait 30 minutes before eating, drinking, or other pills. Self-pay: $149/month for 1.5 mg and 4 mg doses (the 4 mg offer runs through August 31, 2026, then $199) and $299/month for 9 mg and 25 mg. In OASIS-4, the top dose produced about 13.6% average weight loss (up to ~17% for people who stuck with it).

More detail: how to get the Wegovy pill online

Quick note: Rybelsus and Ozempic tablets are also oral semaglutide, but they’re approved for type 2 diabetes, not weight loss. Don’t try to swap tablet and injection doses on your own.

Best Mounjaro alternative for type 2 diabetes (not weight loss)

If you take Mounjaro for type 2 diabetes, the best alternative is not automatically the best weight-loss drug. Your clinician may consider Ozempic, Rybelsus or Ozempic tablets, Trulicity, metformin, or other diabetes medicines based on your A1C, kidney and heart history, side effects, and what your plan covers. Importantly, Zepbound is approved only for weight loss and sleep apnea — it is not a like-for-like diabetes substitute.

If Mounjaro was managing your diabetes, the question isn’t “which drug melts the most weight?” It’s “which medicine keeps my A1C in range, fits my health history, and is covered?” The usual candidates:

• Ozempic (semaglutide, weekly shot) — strong blood-sugar control and heart-risk benefit in people with diabetes.
• Rybelsus or Ozempic tablets (oral semaglutide, daily pill) — needle-free diabetes options.
• Trulicity (dulaglutide, weekly shot) — another once-weekly GLP-1 for diabetes.
• Metformin, SGLT2 inhibitors, and others — your doctor may combine or switch based on the full picture.

Bring your current numbers and history to a prescriber and let them choose. More context: best GLP-1 for diabetes.

What if Mounjaro side effects are why you’re switching?

If side effects are why you’re leaving Mounjaro, the best alternative is not automatically the strongest drug or the cheapest one. Ask your prescriber whether the real issue was dose escalation, dehydration, meal size, or tirzepatide itself. A single-hormone semaglutide option like Wegovy may be considered, but only your clinician should set the switch plan.

Switching drugs doesn’t automatically fix side effects, because GLP-1 and dual GIP/GLP-1 medicines share a similar stomach-side-effect profile. Sometimes the smarter move is a slower dose ramp, better hydration, smaller meals, or a different medication — not the most powerful one. If you couldn’t tolerate Mounjaro, “gentler” may beat “stronger.”

Use this to steer the conversation with your prescriber:

What’s the cheapest Mounjaro alternative without insurance?

The cheapest safe path is usually not the lowest advertised price. Start by checking whether Mounjaro or an alternative is covered (a free coverage check takes minutes), then compare manufacturer self-pay programs for FDA‑approved drugs.

Before you assume you’re stuck paying full price, two quick checks:

1. Are you actually shut out? If you have commercial insurance, even Mounjaro’s savings card can bring it to about $499/month when your plan doesn’t cover it (and as low as $25 when it does) — for an FDA‑approved use, if you qualify. Worth ruling out first.
2. Then compare FDA‑approved cash prices. Watch the offer dates — they change:

Sources: NovoCare; Eli Lilly. Prices and offer dates change — re-check before you buy.

The honest takeaway: the “cheapest” FDA‑approved weight-loss path is a pill at $149/month, and the closest-to-Mounjaro path is $299/month. That’s a long way down from $1,112 — without stepping outside FDA‑approved medicine.

What if your insurance dropped Mounjaro?

Insurance and pharmacy-benefit changes are common. You usually have three moves: switch to the drug your plan now prefers, file a coverage exception or appeal, or use a manufacturer self-pay program. A telehealth concierge can run your coverage and handle the appeal paperwork for you.

Getting that “no longer covered” letter feels like the rug got pulled out. Here’s the playbook, by denial reason:

Plans often cover Mounjaro for diabetes but not for weight loss, and Medicare Part D doesn’t cover any GLP-1 for weight loss today (a federal rule). If you already tried the preferred drug, can’t tolerate it, or your clinician believes it isn’t right for you, ask your plan about a formulary exception or appeal. More context: Mounjaro providers that accept insurance.

If you’re on Medicare: Part D excludes weight-loss GLP-1s today, but CMS is running a short-term Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027. Eligible Part D members can get certain GLP-1 drugs — including Foundayo — for a $50 copay, with prior authorization. It runs outside the normal Part D benefit, so your deductible doesn’t apply and the $50 doesn’t count toward your yearly out-of-pocket total. Check the CMS GLP-1 Bridge page for the current product list and eligibility. More detail: Medicare GLP-1 Bridge $50 copay guide.

Where should you actually start online?

For FDA‑approved Mounjaro alternatives, start with a telehealth program that can check your insurance, route you to the right medication, and show the price before you commit. Before we point you anywhere, here’s the proof — what each option says versus what we could actually confirm:

Ro — best all-around for FDA‑approved alternatives plus insurance help. Ro carries the full FDA‑approved lineup (Wegovy pen and pill, Zepbound KwikPen and vials, Foundayo, Ozempic, Saxenda), matched to LillyDirect/NovoCare pricing. Its free GLP-1 Insurance Coverage Checker shows your real cost before you pay anything, and if you move forward, the concierge submits the paperwork. Cash-pay patients can get a first dose in under a week; with insurance it’s about two weeks while coverage is confirmed. Membership is $39 the first month, then $149/month, or as low as $74/month paid annually — and if you don’t qualify for treatment, you’re not charged the ongoing fee.

Sesame — best if you want provider choice. Sesame is a marketplace: you pick your clinician, and it offers Costco-member pricing on its weight-loss program. The subscription is $99/month, or $59/month on an annual plan, with medication billed separately. One structural perk: Sesame isn’t a pharmacy and doesn’t sell the medication, so your provider has no incentive to push one drug over another.

A real member’s take on Ro. Hannah, a Ro member, summed up the part this page is really about — the insurance fight. She said she hadn’t expected the help, and was “thrilled to not have to fight for my coverage.” (Ro member; compensated for her testimonial. An individual service experience, not a medical result or a guarantee of coverage.)

Want help choosing a program rather than a drug? See: best GLP-1 online programs · Ro vs. LillyDirect · Ro GLP-1 reviews

Switching from Mounjaro: what to ask before you start

People switch between GLP-1 medicines all the time, but doses are not interchangeable between drugs, so a prescriber should set your starting dose and timing. A few minutes of questions now saves you months of regret. Bring these to the table.

Ask your prescriber:

• Is this for weight loss, diabetes, sleep apnea, or heart-risk — and which alternatives are FDA‑approved for my situation?
• What starting dose, and do I need a gap after my last Mounjaro dose?
• Which side effects should make me call you?
• I had side effects on Mounjaro — does that change your recommendation?

Ask your insurance plan:

• Is Zepbound covered? Wegovy? Foundayo? Is Ozempic covered only for diabetes?
• Is prior authorization required, and what diagnosis is needed?
• Are weight-loss medications excluded from my plan entirely?

Ask the provider (telehealth or clinic):

• What’s the membership fee, and is medication included or separate?
• What’s the price after any intro month?
• Which pharmacy fills it, and can I cancel online?
• Do you handle prior authorization if my insurance pushes back?

What not to do: don’t overlap two GLP-1s, don’t copy a dose off a forum, and don’t assume “same active ingredient” means “same product” — a compounded version is not the FDA‑approved drug.

Side effects and safety to know

All GLP-1 medicines share a similar safety profile: common stomach side effects and rare but serious risks. They carry a boxed warning about thyroid tumors and should not be used by people with a personal or family history of medullary thyroid cancer or the condition MEN2. Pancreatitis and gallbladder problems are also possible.

Common side effects are mostly digestive: nausea, vomiting, diarrhea, constipation, and reduced appetite. They tend to be worst when you start or raise the dose, which is why every one of these drugs starts low and increases slowly.

Serious risks are uncommon but real. These medicines carry a boxed warning about thyroid C-cell tumors; don’t use them if you or a close family member has had medullary thyroid carcinoma or MEN2. Pancreatitis, gallbladder issues, and dehydration from heavy vomiting can also happen. Call your provider for severe belly pain, persistent vomiting, or signs of dehydration.

One more safety rule worth repeating: skip the gray market. The FDA warns that products sold as “research-grade,” counterfeit GLP-1s, or knockoffs sold online can contain the wrong ingredients, too much or too little drug, or harmful ingredients. Watch for telehealth red flags: claims that a compounded drug is the “same as” an approved one, prices that seem too good to be true, medicine that arrives looking different or with no instructions, no real screening or prescription, or a pharmacy name that looks off.

How we ranked the best Mounjaro alternatives

Our ranking is based on what changes your decision: FDA‑approved use, average weight loss in clinical trials, current verified self-pay price, how well each fits a specific reason for leaving Mounjaro, and material safety or access caveats. It is not based on commissions.

We weighed five things, roughly in this order:

1. Does the FDA‑approved label match what you’re trying to do?
2. How close is it to Mounjaro for your goal?
3. How clear and affordable is the real price and access path?
4. Shot-vs-pill fit?
5. The strength of the evidence behind it?

“Best for” labels are our editorial judgment based on verified facts — not medical advice, and not a claim that one drug is safer or works better for you personally. We use the RX Index Score methodology: qualitative assessment across clinical legitimacy, care quality, transparency, access, and cost.

Frequently asked questions about the best Mounjaro alternatives

What is the closest alternative to Mounjaro?

Zepbound is usually the closest FDA‑approved alternative for weight loss, because it contains the same active ingredient as Mounjaro (tirzepatide) but is a different FDA‑approved product, labeled for weight management instead of diabetes.

Is Zepbound the same as Mounjaro?

They share the same active ingredient (tirzepatide) and the same dose strengths, but they are two different FDA‑approved products with different labels. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management and sleep apnea.

Is Wegovy better than Mounjaro?

Not universally. In a head-to-head trial, tirzepatide produced more average weight loss than semaglutide, 20.2% versus 13.7%. But Wegovy is FDA‑approved for weight loss, may be cheaper or better tolerated for some people, and is covered by more plans.

Is Ozempic a good Mounjaro alternative?

For diabetes, yes. For weight loss only, Ozempic is off-label and usually not covered, so an obesity-approved drug like Zepbound or Wegovy is a cleaner fit.

What is the best oral (pill) alternative to Mounjaro?

For weight loss, the two FDA‑approved pills are Foundayo (orforglipron) and the Wegovy pill (oral semaglutide), both starting around $149 per month.

What is cheaper than Mounjaro without insurance?

For weight loss, the Wegovy pill and Foundayo start at $149 per month, and Zepbound vials start at $299 per month — all well below Mounjaro’s $1,112.16 list price.

Can I switch from Mounjaro to Wegovy?

Often yes, but a prescriber must set your dose and timing because the drugs are not dose-for-dose equivalent. Many people switch when their insurance changes which drug it prefers.

Are compounded GLP-1s the same as Mounjaro?

No. Compounded GLP-1 products are not FDA‑approved finished drugs, and the FDA has sent waves of warning letters to companies that marketed them as the same as approved medicines.

Is there an over-the-counter Mounjaro alternative?

No over-the-counter supplement works like prescription Mounjaro, Zepbound, Wegovy, Ozempic, or Foundayo. Products marketed as “natural Ozempic” are not equivalent.

What is the best Mounjaro alternative for diabetes?

That depends on your A1C, other health conditions, and coverage. Ask your clinician about Ozempic, Rybelsus or Ozempic tablets, Trulicity, metformin, and other diabetes options.

Is Foundayo a Mounjaro alternative?

Yes, for some people who want an FDA‑approved oral weight-loss option. It is not tirzepatide, and it is the newest of these drugs, so it has the shortest real-world track record.

Related reading

• Best Zepbound alternatives 2026
• Best Wegovy alternatives 2026
• Best Ozempic alternatives 2026
• Foundayo cost without insurance
• Best Foundayo providers
• How to get the Wegovy pill online
• Best GLP-1 for type 2 diabetes
• Best GLP-1 online programs
• Compounded GLP-1 vs. name brand
• Ro vs. LillyDirect
• Ro GLP-1 reviews
• Mounjaro providers that accept insurance
• Medicare GLP-1 Bridge $50 copay guide

The bottom line

If you’re leaving Mounjaro for weight loss and cost is the driver, Zepbound is almost certainly your answer — same active ingredient, FDA‑approved for the use you actually want, from $299 a month instead of $1,112. If needles are the problem, Foundayo or the Wegovy pill gets you there from $149. If insurance is the problem, a free coverage check through Ro takes three minutes and may reveal you’re already covered.

The one situation where “just switch” is the wrong advice: if you take Mounjaro for diabetes. That’s a different lane, and the alternatives are different drugs with different labels. Bring your full history to a prescriber, not a search result.

Sources

1. U.S. Food and Drug Administration — approval and label details for Mounjaro (type 2 diabetes), Zepbound (weight management and OSA), Wegovy (weight management; cardiovascular-risk reduction; MASH), Foundayo (orforglipron, approved April 1, 2026), and Ozempic (type 2 diabetes).
2. Eli Lilly — Zepbound Self Pay Journey vial pricing and terms (LillyDirect); Mounjaro list price $1,112.16 and savings-card tiers; Foundayo approval announcement and ATTAIN-1 results; Zepbound FDA label (OSA indication; “concomitant GLP-1 use not recommended”).
3. NovoCare / Novo Nordisk — Wegovy pen, Wegovy HD (7.2 mg), Wegovy pill, and Ozempic self-pay pricing (verified June 17, 2026); intro offer terms.
4. New England Journal of Medicine — SURMOUNT-5 (tirzepatide 20.2% vs. semaglutide 13.7%); SURMOUNT-1; STEP-1; STEP UP; OASIS-4.
5. U.S. Food and Drug Administration — “Concerns with Unapproved GLP-1 Drugs” (adverse-event counts: 990 compounded semaglutide / 730+ compounded tirzepatide as of May 31, 2026; dosing errors; red flags); compounding enforcement dates; “FDA Warns 30 Telehealth Companies” (March 3, 2026); “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List” (April 30, 2026).
6. Reuters — FDA sends 25 additional warning letters to compounding telehealth companies (June 16, 2026).
7. Centers for Medicare & Medicaid Services (CMS) — Medicare GLP-1 Bridge: $50 copay, July 1, 2026 start, prior authorization required, outside normal Part D benefit.
8. Ro — weight-loss program pricing, formulary, insurance-concierge workflow, and verified member testimonial (June 17, 2026).
9. Sesame — weight-loss program pricing and Trustpilot rating (June 17, 2026).

Medical disclaimer: This page is for information only and is not medical advice. Decisions about starting, stopping, switching, or dosing any medication must be made with a licensed clinician. We maintain a strict separation between FDA‑approved medications and compounded products, and never treat the two as equivalent.

The RX Index is independent guidance for choosing your GLP-1 path. We reviewed FDA labels and safety updates, CMS guidance, manufacturer and provider pricing pages, and real patient discussion themes, and we keep this page on a monthly re-check schedule. Some links go to partners who pay us a commission; this never changes our rankings or the facts. Last verified June 17, 2026.